MDI and DPI Drug Products
...The guidance sets forth information that should be provided to ensure continuing drug.....elastomeric, plastic components or coatings of the container and closure system when in.....manufacturing, processing, packaging, controls, stability testing, or labeling operations..
http://www.fda.gov/cder/guidance/2180dft.pdf (score=100)

Review - Laronidase (Aldurazyme)
...The analytical methods used to evaluate the quality attributes of the final container drug.....Updated data from the stability studies will be provided during the review of this.....final container drug product is requested for 24 months stored at 2­8oC. Expiration dating will be..
http://www.fda.gov/cder/biologics/review/larobio043003r4.pdf (score=87)

stability guidance -draft
...If testing of the drug product in the immediate container or as marketed is needed, the samples.....satisfactory product stability, which may in turn include, but not be limited to, full long-term.....The stability of the drug product after reconstituting or diluting according to labeling..
http://www.fda.gov/cder/guidance/1707dft.pdf (score=73)

HUMAN DRUG CGMP NOTES, June 1997
...2) For finished product stability testing, is it necessary to sample from an unopened container at.....Welcome to another edition of Human Drug CGMP Notes, our periodic memo on CGMP for human.....2) For finished product stability testing, is it necessary to sample from an unopened container at..
http://www.fda.gov/cder/hdn/cnotes67.htm (score=70)

Packaging
...If there is a need for interchangeability of container/closure materials for the drug product from one composition or supplier of a.....Samples of a drug that are selected for stability studies should be packaged in the container/clsoure system in which.....This information should include the proposed market package for the product and the relevant stability and..
http://www.fda.gov/cder/guidance/package.htm (score=61)

PET Drug Products … Current Good Manufacturing Practice (CGMP)
...ensure that each batch of PET drug product meets its established acceptance criteria, 1201.....stability parameters include radiochemical identity and purity, appearance, pH, stabilizer.....made to verify that the correct label has been affixed to the container and the shield..
http://www.fda.gov/cder/guidance/4259dft.pdf (score=59)

Guidanc for Industry: Container and Closure Integrity Testing in Lieu of...
...testing of drugs, and provides a general indication of the information on product.....test with an appropriate container and closure integrity test in the stability protocol.....microbial barrier, and, hence, the sterility of a drug product throughout its shelf..life..
http://www.fda.gov/cber/gdlns/contain.pdf (score=58)

Guidance for Industry
...ensuring that the drug product provided to the patient has the appropriate identity, strength.....medical gas would be tested for stability in the exact container closure system that it is.....if the condition of the drug product, as a result of storage or shipping, casts doubt on the..
http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0165-gdl0001.pdf (score=58)

HUMAN DRUG CGMP NOTES March 1998
...This means that even though a drug product is not sterile, a firm must follow written.....Likewise, microorganisms that react with, or potentially damage the integrity of, the.....For example, microbial content that adversely affects product stability, would be..
http://www.fda.gov/cder/hdn/cnotes38.htm (score=84)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....A description of the container closure system for the drug substance should be provided.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/cder/guidance/3969DFT.pdf (score=68)

þÿ
...18 The applicant and/or drug product manufacturer must establish the reliability of the.....A description of the container closure system for the drug substance should be provided.....should explain the scientific reasons why a stability indicating procedure is not viable..
http://www.fda.gov/OHRMS/DOCKETS/98fr/2003d-0571-gdl0001.pdf (score=66)

Guideline for Submitting Supporting Documentation
...Approval of reprocessing procedures must be obtained before release of the reprocessed drug or drug.....Information relating to the container, closure, stability, and labeling are discussed in.....List all substances used in the manufacture of a drug product whether or not they appear in the..
http://www.fda.gov/cder/guidance/drugprod.htm (score=65)

Guidance- Content & Format CMC for Vaccine & Related Product
...A list should be provided of all components in the drug product, including drug substance(s)and.....the evidence derived from validation studies which assures that product identity, purity, potency, and stability is preserved for.....A description of the container and closure system, and its compatibility with the drug..
http://www.fda.gov/cber/gdlns/cmcvacc.pdf (score=61)

...This increases the likelihood for 6 administration of the wrong drug product by the 7 wrong.....area, fills 2 the container, and it withdraws, and then the 3 container is sealed and.....For 18 instance, ingress of volatile chemicals might 19 adversely affect the stability of..
http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4040T1.DOC (score=57)

PET Drug Products - Current Good Manufacturing Practice (CGMP)
...Appropriate parameters should be evaluated to establish and document the stability of a PET drug product under.....Container assemblies should be prepared at the beginning of the day before other daily.....Stability testing of the PET drug product should be performed at the highest radioactive concentration, and the whole batch..
http://www.fda.gov/cder/guidance/4259dft.htm (score=57)

ICH; Guidance for Industry Q1D Bracketing and Matrixing Designs for...
...When a secondary packaging system contributes to the stability of the drug product, matrixing can be performed.....Additional examples of matrixing designs for a product with three strengths and three container sizes are given in Tables 3a and.....Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and..
http://www.fda.gov/cber/gdlns/ichq1d.htm (score=55)

Validation of Chromatographic Methods
...Solution stability of the drug substance or drug product after preparation..according to the test method should be evaluated.....and leachables from container and closure or manufacturing process, pesticide in drug.....Data that are generated for acceptance,release, stability, or pharmacokinetics will only..
http://www.fda.gov/cder/guidance/cmc3.pdf (score=53)

þÿ
...differences in the samples for the same drug product should be identified as, for example.....longer intended for marketing, stability testing of that strength or container size and/or.....When a secondary packaging system contributes to the stability of the drug product..
http://www.fda.gov/cber/gdlns/ichq1d.pdf (score=53)

Guidance for Industry: Drug Product: Chemistry, Manufacturing, and Controls...
...Miscellaneous drug product impurities include, for example, container closure system leachables.....Such data can include, for example, stability data on small scale batches of drug product.....stability, container closure systems, analytical procedures and methods validation, sterilization..
http://www.fda.gov/cber/gdlns/drugcmc.htm (score=52)

Microsoft Word - 5320.1.doc
...Description of the Composition of the Drug Product..Description of the drug product composition.....Container Closure System..Description of the container-closure system used for the drug.....2 Post-Approval Stability Protocol and Stability Commitment.. Analytical procedures and testing schedule for..
http://www.fda.gov/cder/mapp/5320.1.pdf (score=51)

Las Vegas Injury Lawyer